Pharmacodynamic target associated with clinical outcome of hospital-acquired pneumonia treatment with cefoperazone/sulbactam
Background: For anti-infective agents, pharmacodynamics (PD) parameters have been proposed as predictors of clinical and microbiological success. Hospital-Acquired Pneumonia (HAP) patients have altered pharmacokinetics (PK) that needs to be considered when dosing antibiotics. We conducted a prospect...
Saved in:
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
2014
|
Online Access: | http://www.scopus.com/inward/record.url?eid=2-s2.0-84858971454&partnerID=40&md5=0456deb2bb4ea23bca355553be5788b1 http://cmuir.cmu.ac.th/handle/6653943832/3920 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Language: | English |
id |
th-cmuir.6653943832-3920 |
---|---|
record_format |
dspace |
spelling |
th-cmuir.6653943832-39202014-08-30T02:35:28Z Pharmacodynamic target associated with clinical outcome of hospital-acquired pneumonia treatment with cefoperazone/sulbactam Narawadeeniamhun Panomvana D. Pongpech P. Athavudhdeesomchok Background: For anti-infective agents, pharmacodynamics (PD) parameters have been proposed as predictors of clinical and microbiological success. Hospital-Acquired Pneumonia (HAP) patients have altered pharmacokinetics (PK) that needs to be considered when dosing antibiotics. We conducted a prospective study to assess (PK/PD) of cefoperazone/sulbactam treatment in HAP patients and to identify patient and PD indices associated with clinical response. Methods: Patients with HAP were identified, and information related to patient demographics, clinical status, antibiotic treatment and clinical outcome were documented. Cefoperazone/Sulbactam plasma concentrations were analyzed by validated High-Performance Liquid Chromatography (HPLC).Patient characteristics and PK/PD related factors were tested for associations with clinical outcome. Results: Twenty eight patients of hospital-acquired pneumonia patients were identified. 26 patients (93.1%) had Acinetobacterbaumannii infection and 2 patients (6.9%) had both of Pseudomonas aeruginosa and Acinetobacterbaumannii infection. At the end of treatment, clinical cure was note in 25 % of patients (7/28), improvement 46.4% (13/28) and 28.5% (8/28) had clinical failure. For microbiology outcome, microbiological eradication was note in 12 /28 (42.9%), 12/28 (42.9%) patients had organism persistence and 4 (14.3%) patients had new infection organism.The time which total cefoperazone concentration exceed the MIC (50% T>MIC) and age of the patient who was less than 60 years were significantly associated with clinical response (p<0.05) Conclusion: The percent of a dosing interval in which thecefoperazone serum concentration is above the MIC (%T>MIC) is strongly associated with clinical outcomeand is essential to the appropriate management of A.baumanii and P.aeruginosa infections. 2014-08-30T02:35:28Z 2014-08-30T02:35:28Z 2012 Article 9751491 http://www.scopus.com/inward/record.url?eid=2-s2.0-84858971454&partnerID=40&md5=0456deb2bb4ea23bca355553be5788b1 http://cmuir.cmu.ac.th/handle/6653943832/3920 English |
institution |
Chiang Mai University |
building |
Chiang Mai University Library |
country |
Thailand |
collection |
CMU Intellectual Repository |
language |
English |
description |
Background: For anti-infective agents, pharmacodynamics (PD) parameters have been proposed as predictors of clinical and microbiological success. Hospital-Acquired Pneumonia (HAP) patients have altered pharmacokinetics (PK) that needs to be considered when dosing antibiotics. We conducted a prospective study to assess (PK/PD) of cefoperazone/sulbactam treatment in HAP patients and to identify patient and PD indices associated with clinical response. Methods: Patients with HAP were identified, and information related to patient demographics, clinical status, antibiotic treatment and clinical outcome were documented. Cefoperazone/Sulbactam plasma concentrations were analyzed by validated High-Performance Liquid Chromatography (HPLC).Patient characteristics and PK/PD related factors were tested for associations with clinical outcome. Results: Twenty eight patients of hospital-acquired pneumonia patients were identified. 26 patients (93.1%) had Acinetobacterbaumannii infection and 2 patients (6.9%) had both of Pseudomonas aeruginosa and Acinetobacterbaumannii infection. At the end of treatment, clinical cure was note in 25 % of patients (7/28), improvement 46.4% (13/28) and 28.5% (8/28) had clinical failure. For microbiology outcome, microbiological eradication was note in 12 /28 (42.9%), 12/28 (42.9%) patients had organism persistence and 4 (14.3%) patients had new infection organism.The time which total cefoperazone concentration exceed the MIC (50% T>MIC) and age of the patient who was less than 60 years were significantly associated with clinical response (p<0.05) Conclusion: The percent of a dosing interval in which thecefoperazone serum concentration is above the MIC (%T>MIC) is strongly associated with clinical outcomeand is essential to the appropriate management of A.baumanii and P.aeruginosa infections. |
format |
Article |
author |
Narawadeeniamhun Panomvana D. Pongpech P. Athavudhdeesomchok |
spellingShingle |
Narawadeeniamhun Panomvana D. Pongpech P. Athavudhdeesomchok Pharmacodynamic target associated with clinical outcome of hospital-acquired pneumonia treatment with cefoperazone/sulbactam |
author_facet |
Narawadeeniamhun Panomvana D. Pongpech P. Athavudhdeesomchok |
author_sort |
Narawadeeniamhun |
title |
Pharmacodynamic target associated with clinical outcome of hospital-acquired pneumonia treatment with cefoperazone/sulbactam |
title_short |
Pharmacodynamic target associated with clinical outcome of hospital-acquired pneumonia treatment with cefoperazone/sulbactam |
title_full |
Pharmacodynamic target associated with clinical outcome of hospital-acquired pneumonia treatment with cefoperazone/sulbactam |
title_fullStr |
Pharmacodynamic target associated with clinical outcome of hospital-acquired pneumonia treatment with cefoperazone/sulbactam |
title_full_unstemmed |
Pharmacodynamic target associated with clinical outcome of hospital-acquired pneumonia treatment with cefoperazone/sulbactam |
title_sort |
pharmacodynamic target associated with clinical outcome of hospital-acquired pneumonia treatment with cefoperazone/sulbactam |
publishDate |
2014 |
url |
http://www.scopus.com/inward/record.url?eid=2-s2.0-84858971454&partnerID=40&md5=0456deb2bb4ea23bca355553be5788b1 http://cmuir.cmu.ac.th/handle/6653943832/3920 |
_version_ |
1681420139631738880 |